Abbvie Inc (NYSE: ABBV)’s stock price has gone rise by 0.15 in comparison to its previous close of 188.57, however, the company has experienced a -2.74% decrease in its stock price over the last five trading days. prnewswire.com reported 2024-10-18 that The Only Product of Its Kind Approved for Use in Four Aesthetic Indications: Temporary Improvement in the Appearance of Moderate to Severe Forehead Lines, Frown Lines, Crow’s Feet Lines, and Now Platysma Bands in Adults1-5 With this Approval, BOTOX® Cosmetic is the First and Only Aesthetic Neurotoxin Product to Temporarily Improve the Appearance of Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands) in Adults1-5 IRVINE, Calif., Oct. 18, 2024 /PRNewswire/ — Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of BOTOX® Cosmetic for temporary improvement in the appearance of moderate to severe vertical bands connecting the jaw and neck (platysma bands) in adults.1 BOTOX® Cosmetic is the first and only product with four aesthetic indication areas: forehead lines, frown lines, crow’s feet lines, and now platysma bands, making it the first product of its kind to go beyond the face.1-5 “Research shows millions of consumers in the U.S. are extremely or very bothered by their platysma bands.6* Until now, treatment options have been limited and with this approval, there is a nonsurgical, injectable option to temporarily improve the look of vertical bands connecting the jaw and neck,” said Darin J.
Is It Worth Investing in Abbvie Inc (NYSE: ABBV) Right Now?
The price-to-earnings ratio for Abbvie Inc (NYSE: ABBV) is above average at 63.17x. The 36-month beta value for ABBV is also noteworthy at 0.62. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 4 rating it as “overweight,” 10 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ABBV is 1.76B, and at present, short sellers hold a 0.84% of that float. The average trading volume of ABBV on October 21, 2024 was 4.74M shares.
ABBV’s Market Performance
ABBV’s stock has seen a -2.74% decrease for the week, with a -2.46% drop in the past month and a 8.78% gain in the past quarter. The volatility ratio for the week is 1.55%, and the volatility levels for the past 30 days are at 1.47% for Abbvie Inc. The simple moving average for the past 20 days is -2.44% for ABBV’s stock, with a 7.06% simple moving average for the past 200 days.
Analysts’ Opinion of ABBV
Many brokerage firms have already submitted their reports for ABBV stocks, with Bernstein repeating the rating for ABBV by listing it as a “Mkt Perform.” The predicted price for ABBV in the upcoming period, according to Bernstein is $203 based on the research report published on October 17, 2024 of the current year 2024.
HSBC Securities, on the other hand, stated in their research note that they expect to see ABBV reach a price target of $185. The rating they have provided for ABBV stocks is “Buy” according to the report published on June 05th, 2024.
Cantor Fitzgerald gave a rating of “Overweight” to ABBV, setting the target price at $200 in the report published on May 17th of the current year.
ABBV Trading at -2.81% from the 50-Day Moving Average
After a stumble in the market that brought ABBV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -5.55% of loss for the given period.
Volatility was left at 1.47%, however, over the last 30 days, the volatility rate increased by 1.55%, as shares sank -2.38% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.81% lower at present.
During the last 5 trading sessions, ABBV fell by -2.74%, which changed the moving average for the period of 200-days by +17.70% in comparison to the 20-day moving average, which settled at $193.58. In addition, Abbvie Inc saw 21.87% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ABBV starting from Hudson Thomas J, who proposed sale 49,170 shares at the price of $189.08 back on Aug 08 ’24. After this action, Hudson Thomas J now owns shares of Abbvie Inc, valued at $9,297,210 using the latest closing price.
GONZALEZ RICHARD A, the EXECUTIVE CHAIRMAN OF BOARD of Abbvie Inc, sale 66,500 shares at $186.52 during a trade that took place back on Aug 05 ’24, which means that GONZALEZ RICHARD A is holding 446,599 shares at $12,403,580 based on the most recent closing price.
Stock Fundamentals for ABBV
Current profitability levels for the company are sitting at:
- 0.27 for the present operating margin
- 0.72 for the gross margin
The net margin for Abbvie Inc stands at 0.1. The total capital return value is set at 0.15. Equity return is now at value 53.93, with 3.82 for asset returns.
Based on Abbvie Inc (ABBV), the company’s capital structure generated 0.91 points at debt to capital in total, while cash flow to debt ratio is standing at 0.26. The debt to equity ratio resting at 10.42. The interest coverage ratio of the stock is 7.71.
Currently, EBITDA for the company is 18.1 billion with net debt to EBITDA at 3.43. When we switch over and look at the enterprise to sales, we see a ratio of 7.11. The receivables turnover for the company is 4.69for trailing twelve months and the total asset turnover is 0.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.81.
Conclusion
In summary, Abbvie Inc (ABBV) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
